Patients presenting with bone metastasis had a mOS of 3.1 months and after 1, 3 and 6 months, survival rates were 75.3%, 46.5% and 19.9% respectively. Symptomatic response to therapy was recorded in 85% of all evaluated patients with bone metastasis. Patients undergoing radiosurgery because of...
Conclusion: This study shows that both LR and HR were well tolerated and effective in short-term relief of dysphagia in patients with inoperable or metastasized esophageal cancer. HR was associated with better long-term relief of ... BD Vermeulen,PM Jeene,J Sijben,... - 《Practical Radiation...
Conflicting evidence exists regarding the value of surgical resection of the primary in stage IV breast cancer patients.The prospective randomized phase III ABCSG-28 POSYTIVE trial evaluated median survival comparing primary surgery followed by systemic therapy to primary systemic therapy in de novo stage...
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017. doi:10.1007/s00259-017-3716-2. Google Scholar Smith M, De Bono J, Sternberg C, Le Moulec S, Oud...
Progression-free survival was also statistically significantly shorter for patients in the standard arm relative to that of patients in the experimental arm (... R Martin,VP Joachim,M Hans-Nicolas,... - 《Journal of the National Cancer Institute》 被引量: 0发表: 2019年 Collagen Fiber Alignment...
PURPOSE: Radioligand therapies targeting prostate-specific membrane antigen (PSMA) have been established for the treatment of metastasized castration-resistant prostate cancer (mCRPC) in the last decade and show promising response rates and a favourable toxicity profile. The aim of this study was to ev...
Long-Term Survival in Patients with Inoperable and Metastasized CancerHumansLung NeoplasmsAntineoplastic AgentsPrevalenceSurvival RateRisk AssessmentRisk FactorsSurvival AnalysisSeeber S.doi:10.1159/000143109Siegfried SeeberS. Karger AGOnkologie
BackgroundLeiomyosarcoma of the mesosigma is a very rare entity, with low 5-year survival rates. Treatment consists of resection of the primary tumor and, if applicable, of synchronous or metachronous metastases. Local treatment options for metastatic disease should be exploited as long as possible...
Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancerBackground: Whole-brain radiotherapy (WBRT) has been the standard of care for multiple NSCLC brain metastases but due to its toxicity and lack of survival benefit, its use in the ...
Their study findings show that both macro- and micrometastatic disease presence negatively impact disease-specific survival (DSS) and overall survival (OS) rates significantly. The results also indicate sentinel lymph node biopsy (SLNB) is a feasible way to accurately stage patients with early ...